Optimizing HIV‐1‐specific CD8+ T‐cell induction by recombinant BCG in prime‐boost regimens with heterologous viral vectors
Open Access
- 19 September 2011
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 41 (12) , 3542-3552
Abstract
The desire to induce HIV‐1‐specific responses soon after birth to prevent breast milk transmission of HIV‐1 led us to propose a vaccine regimen which primes HIV‐1‐specific T cells using a recombinant Mycobacterium bovis bacillus Calmette‐Guérin (rBCG) vaccine. Because attenuated live bacterial vaccines are typically not sufficiently immunogenic as stand‐alone vaccines, rBCG‐primed T cells will likely require boost immunization(s). Here, we compared modified Danish (AERAS‐401) and Pasteur lysine auxotroph (222) strains of BCG expressing the immunogen HIVA for their potency to prime HIV‐1‐specific responses in adult BALB/c mice and examined four heterologous boosting HIVA vaccines for their immunogenic synergy. We found that both BCG.HIVA401 and BCG.HIVA222 primed HIV‐1‐specific CD8+ T‐cell‐mediated responses. The strongest boosts were delivered by human adenovirus‐vectored HAdV5.HIVA and sheep atadenovirus‐vectored OAdV7.HIVA vaccines, followed by poxvirus MVA.HIVA; the weakest was plasmid pTH.HIVA DNA. The prime‐boost regimens induced T cells capable of efficient in vivo killing of sensitized target cells. We also observed that the BCG.HIVA401 and BCG.HIVA222 vaccines have broadly similar immunologic properties, but display a number of differences mainly detected through distinct profiles of soluble intercellular signaling molecules produced by immune splenocytes in response to both HIV‐1‐ and BCG‐specific stimuli. These results encourage further development of the rBCG prime‐boost regimen.Keywords
This publication has 55 references indexed in Scilit:
- Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trialsJournal of Immunological Methods, 2011
- Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccineVaccine, 2009
- Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosisVaccine, 2009
- Comparison of multiple vaccine vectors in a single heterologous prime-boost trialVaccine, 2008
- Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectivenessThe Lancet, 2006
- Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challengeVaccine, 2006
- Morbidity and Mortality in Breastfed and Formula-Fed Infants of HIV-1–Infected WomenJAMA, 2001
- BCG Expressing LCR1 of Leishmania chagasi Induces Protective Immunity in Susceptible MiceExperimental Parasitology, 2000
- Variation in protection by BCG: implications of and for heterologous immunityThe Lancet, 1995
- Risk of human immunodeficiency virus type 1 transmission through breastfeedingThe Lancet, 1992